| __timestamp | Amicus Therapeutics, Inc. | Bio-Techne Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 60716000 |
| Thursday, January 1, 2015 | 47269000 | 119401000 |
| Friday, January 1, 2016 | 71151000 | 140879000 |
| Sunday, January 1, 2017 | 88671000 | 199243000 |
| Monday, January 1, 2018 | 127200000 | 240636000 |
| Tuesday, January 1, 2019 | 169861000 | 264359000 |
| Wednesday, January 1, 2020 | 156407000 | 260583000 |
| Friday, January 1, 2021 | 192710000 | 324951000 |
| Saturday, January 1, 2022 | 213041000 | 372766000 |
| Sunday, January 1, 2023 | 275270000 | 378378000 |
| Monday, January 1, 2024 | 396826000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Bio-Techne Corporation and Amicus Therapeutics, Inc. have shown distinct strategies over the past decade. From 2014 to 2023, Bio-Techne consistently maintained higher SG&A expenses, peaking at approximately $397 million in 2023. This represents a 554% increase from 2014, reflecting their aggressive expansion and investment in administrative capabilities. In contrast, Amicus Therapeutics, while also increasing their SG&A expenses, showed a more conservative growth of 1,229% over the same period, reaching around $275 million in 2023. This difference in approach highlights Bio-Techne's focus on scaling operations rapidly, while Amicus appears to prioritize steady, controlled growth. As we look to 2024, Bio-Techne's data continues, but Amicus's figures are yet to be revealed, leaving room for speculation on their future strategies.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Bio-Techne Corporation
Johnson & Johnson or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Pfizer Inc. and Amicus Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Sanofi and Amicus Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Pharming Group N.V.
Cost Management Insights: SG&A Expenses for Opthea Limited and Amicus Therapeutics, Inc.
Comparing SG&A Expenses: Veracyte, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
ACADIA Pharmaceuticals Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Galapagos NV